Biosergen have completed treatment of the first patient with BSG005
Friday, August 30, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby announce the completion of treatment of the first patient with BSG005Invasive fungal infections represent a serious health threat, claiming 2.5 mill lives annually. There is growing resistance toward current therapy and the lack of broad-spectrum safe therapies has the WHO on high alert. It needs attention, and we need novel effective safe treatments. Biosergen is developing BSG005 designed to be safe, efficacious and broad-spectrum. We have been focusing on the starting our first patient trial in India. As